Using Evidence: Learning from Low-Cost Federal Evidence-Building Activities


October 30, 2019



Learning from Low-Cost Evaluations: 2019 OES Results



Increasing Use of Patient-Generated Health Data (PGHD)A collaboration between OES and HHS





Increasing Use of Patient-Generated Health Data (PGHD)

A collaboration between OES and HHS


The intervention group received a training to place bulk orders for electronic blood glucose flow sheets for patients with diabetes



The **control group** received no training


Increasing Use of Patient-Generated Health Data (PGHD)

A collaboration between OES and HHS











Training and Encouragement to Providers Significantly Increases Patient Use of Flowsheets



Reminder Messages to Patients Significantly Increase Patient Use of Flowsheets



Timely Wage Reporting Among SSI Recipients

A collaboration between OES and SSA





Timely Wage Reporting Among SSI Recipients

A collaboration between OES and SSA

Social Security Administration Important Information



Social Security Administration SSI Wage Reporting Project 3-B-24 Robert M. Ball Bldg. 6401 Security Blvd. Baltimore, MD 21236

April 15, 2015

Please read the important reporting information in this letter.

Reporting Changes to your Supplemental Security Income (SSI) Benefits


This notice is a reminder that you need to tell us about your wages, your income, or other changes that may affect your Supplemental Security Income (SSI) payments. We list other changes you need to report on the back of this notice.

You need to let us know because:

- · you need to receive the correct payment; and
- you may need to pay us back if you receive too much money.

Over 200,000 persons who receive SSI report new wages to us each month. If you do not report your wages to us on purpose, we can stop your SSI payments.

Reminder letters to SSI recipients significantly increase timely reporting of wages



Using Proactive Communication to increase College Enrollment for Post-9/11 GI Bill Beneficiaries A collaboration between OES and VA





Using Proactive Communication to increase College **Enrollment for Post-9/11 GI Bill Beneficiaries** A collaboration between OES and VA

From: Veterans Benefits Administration [mailto:Veteransbenefits@public.govdelivery.com]

Sent: {Date}

To: {Email Address}

Subject: Maximizing Your Post 9/11 GI Bill Education Benefits

{Date}

Dear {First Name},

Enroll full-time this semester to maximize your Post 9/11 GI Bill education benefits. Register online or contact your school's registrar's office to ensure your class schedule is complete.

Potential Benefits of Enrolling Full-Time:



You could earn more money: Each year you delay completing your college degree could cost you up to \$65,000 in lifetime earnings.



You could save money: When you exhaust all 36 months of your Post 9/11 GI Bill 4 education benefits you will be responsible for all costs associated with your education. Enrolling in an extra course this semester, while you still have your education benefits, may not cost you any extra in tuition and fees.




You could increase your student financial aid: Your Post 9/11 GI Bill benefits do not impact your eligibility for additional federal financial aid — like Pell Grants — and you may qualify for additional grants based on your income and family situation. To apply, complete a Free Application for Federal Student Aid (FAFSA) at https://fafsa.ed.gov/.

If You Have Questions or Need Assistance


If you have questions or need assistance with your GI Bill benefits, contact VA at 1-888-GI-BILL-1 (1-888-442-4551). If you use the Telecommunications Device for the Deaf (TDD), the Federal number is 711.

Further information may also be found on our website at https://benefits.va.gov/gibill/.

Proactive Communication Significantly Increases College Enrollment for Post-9/11 GI Bill Beneficiaries



Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System A collaboration between OES and VA





Increasing Vaccine Uptake Among Veterans A collaboration between OES and the Atlanta VA Health Care System

VACCINATION DOCUMENTATION To Your patient is DUE for the following vaccines: Click box to review the clinical reminder findings. Click here to view IMMUNIZATION HISTORY Click here to review a summary of VHA guidance for these vaccines. ***INSTRUCTIONS*** Use language that assumes the patient will get vaccinated - "It is time for your X shot today"



Increasing Vaccine Uptake Among Veterans

A collaboration between OES and the Atlanta VA Health Care System

```
Your patient is DUE for the following vaccines: Click box to review the clinical reminder
   findings.
  CLINICAL REMINDERS DUE
                                      --STATUS-- -- DUE DATE-- -- LAST DONE--
  Pneumococcal PCV13 (Prevnar13)
                                       DUE NOW
                                                   DUE NOW
                                                                 unknown
  Tdap Immunization
                                       DUE NOW
                                                   DUE NOW
                                                                 unknown
  CLINICAL REMINDERS SUMMARY
                                      --STATUS-- -- DUE DATE-- -- LAST DONE--
  Pneumococcal PCV13 (Prevnar13)
                                       DUE NOW
                                                   DUE NOW
                                                                 unknown
  Pneumococcal PPSV23 (Pneumovax)
                                         N/A
                                                                00/00/2007
  Td Immunization
                                                                05/21/2019
                                         DONE
  Tdap Immunization
                                                                 unknown
                                       DUE NOW
                                                   DUE NOW
```



Increasing Vaccine Uptake Among Veterans

A collaboration between OES and the Atlanta VA Health Care System

IMMUNIZATION HISTORY					
Immunization	Series	Date	Facility	Reaction	Info
EPATITIS B - SERIES #1 (HISTORIC*		06/26/2014	ATLANTA VA*		
INFLUENZA (HISTORICAL)		11/24/2009	No Site		<c></c>
		09/20/2007	No Site		
INFLUENZA, UNSPECIFIED FORMULATIO*		07/05/2010	7th Floor		
		11/24/2009	No Site		
		10/02/2009	Kroger		<c></c>
NOVEL INFLUENZA-H1N1-09, ALL FORM*		11/24/2009	No Site		<c></c>
PNEUMOCOCCAL POLYSACCHARIDE PPV23		00/00/2007	No Site		
		03/15/2002	ATLANTA VA*		
		00/00/2002	No Site		
TD(ADULT) UNSPECIFIED FORMULATION	В	11/24/2009	No Site		
VARICELLA RECEIVED ELSEWHERE (HIS*		12/01/2009	PubliX		



Increasing Vaccine Uptake Among Veterans


A collaboration between OES and the Atlanta VA Health Care System

Prevnar-13 Immunization Your patient is DUE for an Prevnar 13 vaccination based on information available to this reminder. 🔽 If the patient expresses concerns, click box to follow example below: a. Establish empathy and credibility - establish a connection i. "I know that you want to do whatever you can to keep yourself healthy - I want the same thing" b. Acknowledge the patient's concern, provider alternative explanation for any myths but do not linger i. "I understand that you are concerned about getting the flu, but the flu vaccine cannot give you the flu - it is a killed vaccine, it doesn't have any live virus." c. Pivot back to the disease and emphasize self-efficacy i. "Getting the flu is serious for anybody, but can be particularly severe for older individuals. However, if you get the flu vaccine today you can reduce your likelihood of getting the flu and reduce the severity of the flu if you do get it. ii. "It will also lessen the likelihood of spreading to others, including the elderly and immunocompromised. I strongly recommend the flu vaccine, I get it myself."



Provider talking points

Provider Reminders and Talking Points Do Not Significantly Increase Proportion of Patients Vaccinated When Due



Study Group
(N: 23,964 Patients Due for Flu Vaccine;
84 care teams)


Definition: Unexpected Result

An effect size or direction that runs counter to what prior evidence or informed hypotheses would suggest.


Definition: Null Result

No statistically significant difference in outcome between an intervention and a control (no-intervention) condition, or between two different interventions or versions of an intervention.

This does NOT mean that we can conclude the intervention is ineffective or that we say the intervention has no effect.




More Null Results in Health Published in Recent Years



Null Results Can Occur for Several Reasons


Results of Field Trials since 2015 by Office of Evaluation Sciences




Reason 1: Baseline take-up rate and outcome




Low Baseline Take-up Associated with Null or Negative Effects in Many Tests of Informational Nudges




Reason 2: Small Sample Size or Mismatched Study Design





Reason 3: Intervention Design Not Strong Enough



Questions to ask when planning a study:

- 1. Does the baseline information about the program, customers, and the outcome suggest they can be changed?
- 2. Does the study design, including the sample size at the level of randomization, provide a strong foundation for detecting a change in outcomes?
- 3. Does the intervention's theory of change match the problem is it trying to solve?

Are the mode, timing, and messenger appropriate and strong enough to address those barriers and change outcomes for the intervention group?

Ways to Interpret and Act on Nulls



Unexpected and Null Results Can Help Build Federal Evaluation Plans and Learning Agendas

Some misconceptions about unexpected or null results in Federal evaluation:

Misconception: Null results are rare.

Truth: All interventions cannot or will not be effective. As noted above, more null results are being published than before for interventions in health and social sciences. One-third of completed evaluations by the Office of Evaluation Sciences (OES) with federal agency partners had null results. As agencies conduct more research, they are likely to encounter studies that do not show

¹ Turner et al. 2008; Franco, Malhotra and Simonovits, 2014; Kaplan and Irvin, 2015; Featherstone, Coffman and Kessler, 2018. https://blogs.worldbank.org/impactevaluations/how-publish-statistically-insignificant-results-economics https://blogs.plos.org/everyone/2015/02/25/positively-negative-new-plos-one-collection-focusing-negative-null-inconclusive-results/

Panel:

Calvin Johnson, Deputy Assistant Secretary
 Office of Policy Development and Research, HUD

 Susan Wilschke, Evaluation Officer, Acting Associate Commissioner
 Office of Research, Demonstration, and Employment Support, SSA

Takeaways:

- 1. When building and using evidence, you will at times experience unexpected results, including null results.
- 2. As you plan studies in the future, consider ways to strengthen the intensity of the intervention being tested, and set expectations about likely effect sizes given the intervention scope and strength.
- 3. All results can be used to advance your evaluation plans and inform program design and implementation.

Learning from Administrative Data

Increasing FAFSA Completion by HUD-Assisted Youth

A collaboration between OES, HUD, and ED





Increasing FAFSA Completion by HUD-Assisted Youth


A collaboration between OES, HUD, and ED






Increasing FAFSA Completion by HUD-Assisted Youth


A collaboration between OES, HUD, and ED























Reducing Inappropriate Prescribing of Quetiapine in Medicare Part D A collaboration between OES and HHS

Posoarci

JAMA Psychiatry | Original Investigation

Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults A Randomized Clinical Trial

Adam Sacarny, PhD; Michael L. Barnett, MD, MS; Jackson Le, PharmD; Frank Tetkoski, RPh; David Yokum, PhD; Shantanu Agrawal, MD

IMPORTANCE Antipsychotic agents, such as quetiapine fumarate, are frequently overprescribed for indications not supported by clinical evidence, potentially causing harm.

OBJECTIVE To investigate if peer comparison letters targeting high-volume primary care prescribers of quetiapine meaningfully reduce their prescribing.

DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial (intent to treat) conducted from 2015 to 2017 of prescribers and their patients nationwide in the Medicare program. The trial targeted the 5055 highest-volume primary care prescribers of quetiapine in 2013 and 2014 (approximately 5% of all primary care prescribers of quetiapine).

INTERVENTIONS Prescribers were randomized (1:1 ratio) to receive a placebo letter or 3 peer comparison letters stating that their quetiapine prescribing was high relative to their peers and was under review by Medicare.

MAIN OUTCOMES AND MEASURES The primary outcome was the total quetiapine days supplied by prescribers from the intervention start to 9 months. Secondary outcomes included quetiapine receipt from all prescribers by baseline patients, quetiapine receipt by patients with low-value or guideline-concordant indications for therapy, mortality, and hospital use. In exploratory analyses, the study followed outcomes to 2 years.

RESULTS Of the 5055 prescribers, 231 (4.6%) were general practitioners, 2428 (48.0%) were in family medicine, and 2396 (47.4%) were in internal medicine; 4155 (82.2%) were male. All were included in the analyses. Over 9 months, the treatment arm supplied 11.1% fewer supplied 11.1%

Editorial page 989

Supplemental content

→ CME Quiz at jamanetwork.com/learning and CME Questions page 1096



Reducing Inappropriate Prescribing of Quetiapine in Medicare Part D

A collaboration between OES and HHS



Reducing Inappropriate Prescribing of Quetiapine in Medicare Part D

A collaboration between OES and HHS

Takeaways:

1. Start data access early



2. Identify agency and contractor data experts



3. Learn what you can do yourself 🦃




Using the Military Health System Opioid Registry to Identify and Reduce Concurrent Opioid-Benzodiazepine Prescriptions A collaboration between OES and DoD






Using the Military Health System Opioid Registry to Identify and Reduce Concurrent Opioid-Benzodiazepine Prescriptions A collaboration between OES and DoD



Using the Military Health System Opioid Registry to Identify and Reduce Concurrent Opioid-Benzodiazepine Prescriptions

A collaboration between OES and DoD



Using the Military Health System Opioid Registry to Identify and Reduce Concurrent Opioid-Benzodiazepine Prescriptions A collaboration between OES and DoD

Patient Look-up

Scan or enter a barcode / EDIPN / SPONSSN to view patient data.

Diagnosis of bipolar or schizophrenia in the past 6 months: 7 pts Diagnosis of sleep apnea in the past 6 months: 3 pts One or more ED visit in past 6 months: 11 pts Hospitalized in past 6 months: 8 pts

NOTE: Please send suggestions/comments/complaints to Judith Rosen and Archie Bockhorst Please select your duty location: Other / Population Health Activity Manual Entry — Suggest Documents Barcode / EDIPN / SPONSSN Go RIOSORD Index Score: 71 - * Recommend Naloxone * MEDD OVER TIME Probability of Opioid Induced Respiratory Depression: 86% Last Naloxone: No record of dispensing in the past year Sole Prescriber: None assigned 205 Opioid Dispensing History:
12/07/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB PHARMACY #678)
11/09/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMÁCY)
10/11/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMÁCY)
10/10/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
10/10/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
08/15/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
06/19/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
06/19/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
04/27/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY)
03/29/2017 TAPENTADOL HCL 75MG #120 DS30 (HEB GROCERY COMPANY LP HEB PHARMACY) 200 128 127 150 123 100 100 Benzo Dispensing History: 12/19/2017 CLONAZEPAM-PO 1MG TAB #60 DS30 (WILFORD HALL AMB SURGICAL CTR) 10/12/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CTR) 09/19/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CTR) 07/30/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CI 06/12/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CI 05/103/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CI 04/11/2017 CLONAZEPAM 1 MG #60 DS30 (WILLFORD HALL MEDICAL CI 03/29/2017 CLONAZEPAM 1 MG #30 DS30 (HEB GROCERY COMPANY LP) 02/17 03/17 04/17 05/17 08/17 07/17 08/17 09/17 10/17 11/17 12/17 01/18 RIOSORD Criteria: **Print Opioids Patient Summary Report** Current MEDD > 100: 16 pts
Diagnosis of opioid dependence in the past 6 months: 15 pts Current benzodiazapene usage: 4 pts **Print Patient Summary Report** Current antidepressant usage: 7 pts



Medications				
Date ▼	Pharmacy Name	Drug Name	Product Name	C
01/04/2018	WILFORD HALL AMB SURGICAL CTR	QUETIAPINE FUMPO 100MG TAB		3
01/04/2018	WILFORD HALL AMB SURGICAL CTR	TRAZODONE HCL 100 MG	TRAZODONE HCL	3
12/27/2017	WILFORD HALL AMB SURGICAL	ESZOPICLONE (LUNESTA OR		3

Using the Military Health System Opioid Registry to Identify and Reduce Concurrent Opioid-Benzodiazepine Prescriptions

A collaboration between OES and DoD

Data Strategies:

- Share de-identified and synthetic data
- Develop a Virtual Data Environment (VDE)
- Reduce barriers to data access
- Streamline agreements processes

Questions and Answers



Upcoming Events: Workshops for Federal Employees

Registration details at oes.gsa.gov/events/

- Evidence-Building Success Stories, 9:00AM-10:15AM, November 22: Interactive session to share success stories of how evidence has been used to strengthen agencies' programs and policies, and share tips and tricks for creating buy-in and excitement around evidence-building activities in your agency
- Mapping Strategy to Evidence, 9:00AM-11:00AM, December 6:
 This workshop will provide an introduction to mapping agency strategy to the new evidence-building activities required under the Evidence Act, including hands-on practice in drafting Learning Agenda priorities

Evidence Act Resources:

- Intergovernmental Personnel Act (IPA) Guide
- Evidence Act Learning Agenda and Evaluation Plan Toolkits
 - Forthcoming resources and training, January 2020

Thank you to our Federal collaborators!



Department of Defense



Department of Health & Human Services



Department of Housing & Urban Development



Department of Veterans Affairs



Social Security Administration

Join our team! Two Fellowship opportunities based in Washington D.C.

- Annual Fellowship: Team members work alongside agency collaborators to apply behavioral insights, make concrete recommendations on how to improve government, and evaluate impact using administrative data. One year fellowships begin in Fall 2020. The application deadline is December 15, 2019.
- Evidence Fellowship: OES is uniquely situated at the center of government to share leading practices, develop resources and build skills in the Federal workforce on evidence and evaluation. Six-month details beginning in January 2020 are open to Federal employees only. Applications are reviewed on a rolling basis; the final application deadline is November 20, 2019.

Apply today! https://oes.gsa.gov/contact/

oes.gsa.gov

oes@gsa.gov